Study | Country | Cohort age (mean ± SD years) (range) | Number of patients (n, female/male) | Mite species (supplier) | TP | FP | FN | TN |
---|---|---|---|---|---|---|---|---|
Heinemann et al. [23] | Germany | 25.4 (18–43) | 52 (37/15) | D. pteronyssinus (ALK-Scherax-Arzneimittel) | 13 | 1 | 10 | 28 |
Wistokat-Wülfing et al. [24] | Germany | NR | 32 (NR) | D. pteronyssinus (ALK-Scherax-Arzneimittel) | 14 | 3 | 7 | 8 |
Lorenzini et al. [25] | Brazil | 9.47 (2–31) | 43 (NR) | A. ovatus (in house) | 0 | 6 | 7 | 30 |
Darsow et al. [26] | Germany | 29 ± 16 (3-69) | 36 (27/9) | D. pteronyssinus (Bencard, Allergopharma) | 8 | 5 | 12 | 11 |
Kutlu et al. [31] | Turkey | 6.9 ± 3.6 (2– 15) | 44 (23/21) | D. pteronyssinus (ALK-Abello, Stallergėnes) | 7 | 2 | 11 | 24 |
Manzini et al. [27] | Italy | (0.5– 63) | 313 (NR) | D. pteronyssinus and D. farina (Bayropharm, Lofarma, Allergopharma | 46 | 76 | 54 | 137 |
Wananukul et al. [28] | Thailand | (2–14) | 30 (NR) | D. pteronyssinus (GREER) | 21 | 0 | 8 | 1 |
Michel et al. [29] | Switzerland | 35.8 (14–73) | 23 (16/7) | D. pteronyssinus (Stallergėnes*) | 6 | 5 | 5 | 7 |
Holm [22] | Sweden | 29 (18–65) | 81 (54/27) | D. pteronyssinus and D. farina (ALK-Abello) | 14 | 23 | 5 | 39 |
Fuiano et al. [30] | Italy | 2.2 ± 2.5 | 15 (NR) | Dermatophagoides (Stallergėnes*) | 1 | 11 | 0 | 3 |